We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Coronavirus Screening Test Developed by Johns Hopkins Microbiologists

By LabMedica International staff writers
Posted on 20 Mar 2020
A team of clinical microbiologists from John Hopkins University (Baltimore, MD) have developed an in-house coronavirus screening test that could allow the health system to test about 1,000 people daily. More...
The test would help people to quickly learn if they are infected with COVID-19 and also allow doctors to test people with whom such patients have come in contact.

The test, which analyzes a nasal or oral swab, was used for the first time on March 11 by the microbiologists who performed around 85 tests during the first three days. The team expects to quickly ramp up capacity and test 180 people per day next week and 500 people in the week after that to reach 1,000 tests per day by early April. Currently, the test delivers results in about 24 hours, which the doctors hope to shorten to three hours.

“We will be able to diagnose more cases. This will allow the control of exposure,” said Heba Mostafa, M.B.B.Ch., Ph.D., assistant professor of pathology and director of the molecular virology laboratory at The Johns Hopkins Hospital.

“Testing is very important in terms of identifying cases so epidemiologists can then contact people exposed to individuals who are known to be positive and make recommendations about home isolation and further follow-up,” added Karen Carroll, M.D., professor of pathology and director of the Division of Medical Microbiology at Johns Hopkins.

Related Links:
John Hopkins University


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.